Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Farhad Kamali.

Newcastle AuthorsTitleYearFull text
Dr Emma Kampouraki
Dr Peter Avery
Dr Tina Biss
Dr Hilary Wynne
Professor Farhad Kamali
et al.
Assessment of exposure to direct oral anticoagulants in elderly hospitalised patients2021
Frances Sidgwick
Dr Andrew Porter
Dr Paul Ayuk
Professor Farhad Kamali
Determination of Dabigatran Concentration in Human Plasma and Breast Milk2021
Dr Emma Kampouraki
Dr Salah Abohelaika
Dr Peter Avery
Dr Tina Biss
Dr Hilary Wynne
et al.
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing2021
Dr Tina Biss
Professor Farhad Kamali
CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis2020
Emma Kampouraki
Dr Hilary Wynne
Dr Peter Avery
Professor Farhad Kamali
Validation of an algorithm to predict decline in INR following warfarin cessation in patients undergoing invasive procedures2020
Dr Paul Ayuk
Dr Emma Kampouraki
Frances Sidgwick
Professor Farhad Kamali
Investigation of dabigatran secretion into breast milk: Implications for oral thromboprophylaxis in post-partum women2019
Dr Emma Kampouraki
Professor Farhad Kamali
Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation2019
Dr Paul Bogowicz
Dr Eilish Gilvarry
Professor Farhad Kamali
Professor Eileen Kaner
Professor Dorothy Newbury-Birch
et al.
Alcohol and other substance use among medical and law students at a UK university: a cross-sectional questionnaire survey2018
Dr Salah Abohelaika
Dr Hilary Wynne
Dr Peter Avery
Dr Emma Kampouraki
Professor Farhad Kamali
et al.
Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery2018
Sal Bakar
Dr Peter Avery
Dr Colin Brown
Professor Ann Daly
Professor Farhad Kamali
et al.
Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case–Control Study2018
Dr Salah Abohelaika
Dr Hilary Wynne
Dr Peter Avery
Dr Lisa Jones
Professor Farhad Kamali
et al.
Individual and monitoring centre influences upon anticoagulation control of AF patients on warfarin: a longitudinal multi-centre UK-based study2018
Dr Peter Avery
Professor Farhad Kamali
Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients2018
Dr Emma Kampouraki
Dr Peter Avery
Dr Hilary Wynne
Dr Tina Biss
Dr John Hanley
et al.
Assessment of the efficacy of a novel tailored vitamin K dosing regimen in lowering the International Normalised Ratio in over-anticoagulated patients: A randomised clinical trial2017
Dr Emma Kampouraki
Dr Peter Avery
Dr Tina Biss
Professor Farhad Kamali
Association between CYP4F2 genotype and circulating plasma vitamin K concentration in children on chronic warfarin therapy: Possible long-term implications for bone development and vascular health2017
Dr Emma Kampouraki
Professor Farhad Kamali
Dietary implications for patients receiving long-term oral anticoagulation therapy for treatment and prevention of thromboembolic disease2017
Professor Ann Daly
Professor Farhad Kamali
A multi-factorial analysis of response to warfarin in a UK prospective cohort2016
Professor Farhad Kamali
Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden2016
Sal Bakar
Professor Farhad Kamali
Dr Colin Brown
Effect of Statins on Functional Expression of Membrane Transporters in L6 Rat Skeletal Muscle Cells2016
Salah Abohelaika
Dr Hilary Wynne
Dr Peter Avery
Dr Patrick Kesteven
Professor Farhad Kamali
et al.
Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management2016
Salah Abohelaika
Dr Hilary Wynne
Dr Peter Avery
Professor Farhad Kamali
Influence of CYP2C9 polymorphism on the fall in International Normalized Ratio in patients interrupting warfarin therapy before elective surgery2015
Professor Farhad Kamali
Professor Ann Daly
Oral anticoagulation: a critique of recent advances and controversies2015
Professor Farhad Kamali
Professor Ann Daly
Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants2015
Dr Salah Abohelaika
Dr Hilary Wynne
Professor Farhad Kamali
The effect of CYP2C9 polymorphism on inr decline in patients stopping warfarin before surgery2015
Salah Abohelaika
Dr Hilary Wynne
Professor Farhad Kamali
The impact of genetics on the management of patients on warfarin awaiting surgery2015
Salah Abohelaika
Professor Farhad Kamali
Dr Peter Avery
Dr Patrick Kesteven
Dr Hilary Wynne
et al.
Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England2014
Salah Abohelaika
Dr Tina Biss
Dr Hilary Wynne
Professor Farhad Kamali
C0170: The Impact of Dietary Vitamin K on the Pharmacological Activity of FXa Inhibitor Rivaroxaban in Man2014
Dr Tina Biss
Professor Farhad Kamali
Characterizing variability in warfarin dose requirements in children using modelling and simulation2014
Professor Farhad Kamali
Genotype-Guided Dosing of Vitamin K Antagonists [Reply]2014
Dr Tina Biss
Dr Peter Avery
Emily Swinburne
Professor Farhad Kamali
Maintenance warfarin dose in children is determined by S-warfarin clearance which is in turn influenced by CYP2C9 genotype2014
Professor Ann Daly
Professor Farhad Kamali
Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy2014
Salah Abohelaika
Dr Tina Biss
Dr Peter Murphy
Professor Farhad Kamali
The impact of dietary vitamin K on the pharmacological activity of FXa inhibitor rivaroxaban in man2014
Dr Patrick Kesteven
Professor Ann Daly
Dr Peter Avery
Professor Farhad Kamali
A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study2013
Dr Patrick Kesteven
Julian Leathart
Professor Ann Daly
Professor Farhad Kamali
A Randomized Trial of Genotype-Guided Dosing of Warfarin2013
Professor Farhad Kamali
Dr Hilary Wynne
Dr Patrick Kesteven
Dr John Hanley
Dr Jing Shen
et al.
Improving the safety and efficacy of anticoagulation therapy for thromboembolic disease through Vitamin K2013
Dr Jeremy Palmer
Professor Farhad Kamali
Quality of bevacizumab compounded for intravitreal administration2013
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children2013
Professor Ann Daly
Professor Farhad Kamali
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs2012
Professor Farhad Kamali
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users2012
Professor Farhad Kamali
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data2012
Dr Ellen Hatch
Dr Iain Matthews
Professor Ann Daly
Professor Farhad Kamali
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors2012
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Professor Farhad Kamali
VKORC1 and CYP2C9 genotype is associated with over-anticoagulation during initiation of warfarin therapy in children2012
Dr Tina Biss
Professor Farhad Kamali
Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?2012
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Professor Farhad Kamali
Warfarin dose prediction in children using pharmacogenetics information2012
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Warfarin dose prediction in children using pharmacogenetics information2012
Dr Tina Biss
Dr Peter Avery
Julian Leathart
Dr John Hanley
Professor Ann Daly
et al.
VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children2011
Professor Farhad Kamali
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data2011
Dr Peter Avery
Professor Farhad Kamali
A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy2011
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children2011
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Comparison of time within therapeutic INR range with percentage INR within therapeutic range for assessing long-term anticoagulation control in children [reply to a rebuttal]2011
Lilian Fairbairn Smith
Dr Wei Cope
Professor Farhad Kamali
Dr Hilary Wynne
Effect of provision of the NHS NPSA oral anticoagulant therapy patient information pack upon patients' knowledge and anticoagulant control2011
Dr Tina Biss
Professor Ashley Adamson
Emeritus Professor Chris Seal
Professor Farhad Kamali
The potential impact of dietary vitamin K status on anticoagulation control in children receiving warfarin2011
Dr Tina Biss
Dr Peter Avery
Professor Farhad Kamali
Warfarin treatment outcomes in children monitored at home with a point-of-care device2011
Professor Ann Daly
Professor Farhad Kamali
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives2010
Professor Farhad Kamali
Dr Hilary Wynne
Pharmacogenetics of warfarin2010
Dr Peter Avery
Professor Farhad Kamali
Proposal of a pharmacogenetic-based dosing algorithm for the induction of warfarin anticoagulation therapy in patients with thromboembolic disease2010
Dr Montserrat Briz Del Blanco
Dr Katherine Talks
Dr John Hanley
Dr Patrick Kesteven
Professor Ann Daly
et al.
Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study2010
Professor Farhad Kamali
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups2010
Professor Farhad Kamali
Professor Ann Daly
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data2009
Professor Farhad Kamali
Professor Ann Daly
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study2009
Professor Farhad Kamali
Professor Ann Daly
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design2009
Dr Katherine Talks
Dr John Hanley
Dr Patrick Kesteven
Dr Peter Avery
Professor Ann Daly
et al.
Individualised oral vitamin K for reversal of warfarin excessive anticoagulation2009
Professor Farhad Kamali
Novel oral anticoagulant and diet: the potential for interaction2009
Professor Farhad Kamali
Dr Hilary Wynne
Pharmacogenetics and anticoagulation therapy2009
Professor Farhad Kamali
Peter Wood
Alan Ward
Vitamin K deficiency amplifies anticoagulation response to ximelagatran: possible implications for direct thrombin inhibitors and their clinical safety2009
Dr Ellen Hatch
Dr Hilary Wynne
Dr Peter Avery
Professor Farhad Kamali
Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients2008
Elizabeth Sconce
Dr Hilary Wynne
Professor Farhad Kamali
Factors Affecting Anticoagulation Response to Warfarin2008
Professor Farhad Kamali
Individual Patient Meta-Analysis of Self-Monitoring of an Oral Anticoagulation Protocol2008
Elizabeth Sconce
Dr Peter Avery
Dr Hilary Wynne
Professor Farhad Kamali
Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism influences the anticoagulation response subsequent to vitamin K intake: A pilot study2008
Dr Ellen Hatch
Elizabeth Sconce
Dr Barry King
Dr Hilary Wynne
Professor Ann Daly
et al.
Polymorphisms in genes associated with the vitamin K epoxide reductase complex do not affect warfarin dose requirement2007
Elizabeth Sconce
Dr Peter Avery
Dr Hilary Wynne
Professor Farhad Kamali
Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin2007
Elizabeth Sconce
Dr Hilary Wynne
Professor Farhad Kamali
Vitamin K supplementation during oral anticoagulation: No real cause for concern [2]2007
Dr Ellen Hatch
Elizabeth Sconce
Professor Ann Daly
Professor Farhad Kamali
A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene2006
Elizabeth Sconce
Professor Ann Daly
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
et al.
APOE genotype makes a small contribution to warfarin dose requirements2006
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al.
Apolipoprotein E polymorphisms do not make a clinically significant contribution to warfarin dose requirements2006
Elizabeth Sconce
Professor Farhad Kamali
Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: The need for a more tailored dosing regimen2006
Dr Hilary Wynne
Dr Tayyaba Khan
Dr Peter Avery
Peter Wood
Professor Farhad Kamali
et al.
Dietary related plasma vitamin C concentration has no effect on anticoagulation response to warfarin2006
Professor Farhad Kamali
Genetic influences on the response to warfarin2006
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al.
Simvastatin results in a lower warfarin dose requirement due to a reduced clearance of warfarin2006
Professor Farhad Kamali
The future prospects of pharmacogenetics in oral anticoagulation therapy2006
Elizabeth Sconce
Dr Tayyaba Khan
Professor Ann Daly
Dr Hilary Wynne
Professor Farhad Kamali
et al.
The impact of simvastatin on warfarin disposition and dose requirements2006
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
[abstract] CYP2C9 polymorphisms and haplotypes: correlation with warfarin dose and metabolism2005
Chen Chen
Professor Farhad Kamali
[abstract] Investigation of the effect of Chinese herbal medicines on the anticoagulation effect of warfarin using hepatic microsomes in vitro2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Patrick Kesteven
Dr Peter Avery
et al.
[abstract] Pfizer poster communication prize - The influence of patient age, CYP2C9 genotype and height on warfarin dose requirements2005
Professor Farhad Kamali
A comparison of the antinociceptive and adverse effects of a mu-opioid receptor agonist with a delta-opioid receptor agonist2005
Dr Tayyaba Khan
Elizabeth Sconce
Professor Farhad Kamali
Factors contributing to the stability of anticoagulation control and outcome of thromboembolic prophylaxis in the older population2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Professor Farhad Kamali
Patients with unstable control have a poorer dietary intake of vitamin K compared with patients with stable control of anticoagulation2005
Elizabeth Sconce
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Barry King
et al.
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen2005
Professor Farhad Kamali
V-10153 Vernalis2005
Professor Farhad Kamali
V-10153 Vernalis. A New thrombolytic agent2005
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Dr Patrick Kesteven
Peter Wood
et al.
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin2004
Dr Tayyaba Khan
Dr Hilary Wynne
Dr Peter Avery
Dr Patrick Kesteven
Professor Farhad Kamali
et al.
Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin2004
Professor Farhad Kamali
Dr Tayyaba Khan
Dr Barry King
Professor Ann Daly
Dr Hilary Wynne
et al.
The impact of patient age and genetic polymorphism of CYP2C9 on warfarin dose requirements2004
Dr Tayyaba Khan
Professor Farhad Kamali
Dr Patrick Kesteven
Dr Peter Avery
Dr Hilary Wynne
et al.
The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation2004
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism2004
Professor Farhad Kamali
[Book Review] Introduction to drug metabolism2003
Dr Barry King
Dr Tayyaba Khan
Professor Farhad Kamali
Professor Ann Daly
Novel CYP2C9 polymorphisms and their relationship to warfarin dose requirements2003
Helen Hickmott
Dr Hilary Wynne
Professor Farhad Kamali
The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements2003
Professor Farhad Kamali
Dr Hilary Wynne
The effect of stability of oral anticoagulant therapy upon patient-perceived health status and quality of life [4]2003
Dr Hilary Wynne
Dr Patrick Kesteven
Professor Farhad Kamali
The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life2003
Professor Farhad Kamali
Professor Ann Daly
Dr Hilary Wynne
Warfarin sensitivity: Be aware of genetic influence2003
Professor Farhad Kamali
Stereoselectivity in thioridazine metabolism in vitro2002
Professor Dorothy Newbury-Birch
Dr Ray Lowry
Professor Farhad Kamali
The changing pattern of drinking, illicit drug use, stress, anxiety and depression in dental students: a longitudinal study (authors reply)2002
Professor Dorothy Newbury-Birch
Dr Ray Lowry
Professor Farhad Kamali
The changing patterns of drinking, illicit drug use, stress, anxiety and depression in dental students in a UK dental school: A longitudinal study2002
Professor Farhad Kamali
Dr Hilary Wynne
The impact of stability of oral anticoagulant therapy upon patient perceived health status and quality of life2002
Professor Farhad Kamali
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a Pk-PD modelling analysis.2001
Professor Dorothy Newbury-Birch
Dr David Walshaw
Professor Farhad Kamali
Drink and drugs: From medical students to doctors2001
Professor Dorothy Newbury-Birch
Professor Farhad Kamali
Psychological stress, anxiety, depression, job satisfaction, and personality characteristics in preregistration house officers2001
Professor Farhad Kamali
Dr Hilary Wynne
Dr Patrick Kesteven
Temporal variations in plasma vitamin K and lipid concentrations and clotting factor activity in humans2001
Professor Farhad Kamali
Almotriptan Almirall Prodesfarma SA2000
Professor Farhad Kamali
Dr Tim Butler
The contribution of plasma (R)- and (S)-warfarin and vitamin K concentrations to intra-individual variability in anticoagulation2000
Professor Farhad Kamali
Dr Tim Butler
Dr Hilary Wynne
The influence of (R)- and (S)-Warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation2000
Professor Farhad Kamali
Alcohol and illicit drug use in medical students and junior doctors at Newcastle University: a longitudinal study1999
Professor Farhad Kamali
Assessment of the relationship between analgesia and plasma concentrations of dihydrocodeine and dihydromorphine following dihydrocodeine administration1999
Professor Farhad Kamali
BMS-181885-Bristol Myers Squibb1999
Professor Farhad Kamali
Ditropan XL1999
Professor Farhad Kamali
Ditropan-XL-Alza Corp1999
Helen Hickmott
Professor Farhad Kamali
Effect of racemic and (R)- and (S)-warfarin on carboxylase activity and the vitamin K cycle1999
Professor Farhad Kamali
Job satisfaction and stress in pre-registration house officers in the north east of England1999
Professor Farhad Kamali
KMD-3213-Kissei Pharmaceutical Co Ltd1999
Professor Farhad Kamali
Emeritus Professor Robin Seymour
Phenytoin metabolism to 5-(4-hydroxyphenyl)-5-phenylhydantoin (HPPH) in man, cat and rat in vitro and in vivo, and susceptibility to phenytoin-induced gingival overgrowth1999
Professor Farhad Kamali
Rofecoxib- Merck & Co Inc1999
Professor Farhad Kamali
Talsaclidine fumarate-Boehringer Ingelheim Corp1999
Professor Farhad Kamali
Dr David Ball
Emeritus Professor Robin Seymour
The effect of multiple anticonvulsant therapy on the expression of phenytoin-induced gingival overgrowth1999
Professor Farhad Kamali
Russell Wallace
Professor Alan Calvert
The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-migraine drug, in healthy volunteers1996